Skip directly to content

Xalkori▼ (crizotinib)

What is XALKORI® and what is it used for?

XALKORI® as monotherapy is indicated for1:         

  • The first-line treatment of adults with ALK-positive advanced NSCLC
  • The treatment of adults with previously treated ALK-positive advanced NSCLC
  • The treatment of adults with ROS1-positive advanced NSCLC

XALKORI® is a cancer medicine used on its own to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC), when the disease is advanced2:

  • It is used if the NSCLC is ‘ALK-positive’, which means that the cancer cells contain certain changes affecting the gene responsible for a protein called ALK (anaplastic lymphoma kinase).
  • It is also used when the NSCLC is ‘ROS1-positive’. This means that the cancer cells contain changes affecting the gene responsible for the protein ROS1.

ALK and ROS1 belong to a family of proteins called receptor tyrosine kinases (RTKs), which are involved in the growth of cells. In patients either ‘ALK-positive’ or ‘ROS1-positive’, the ALK or ROS1 protein is abnormally active and can promote the growth of cancer cells and the development of new blood vessels that supply them2.

The active substance in XALKORI®, crizotinib, is an RTK inhibitor. It works mainly by blocking the activity of ALK or ROS1, including when the genetic change is present, thereby reducing the growth and spread of the cancer in ALK-positive or in ROS1-positive NSCLC2.

The medicine can only be obtained with a prescription.

 

Reference information
  • The National Institute for Health and Care Excellence (NICE) provides national guidance and advice to improve health and social care. One of the ways they do this is by producing evidence based guidance. See NICE guidance on XALKORI®.
  • The European Medicines Agency (EMA) is an agency of the European Union (EU), located in London. The Agency is responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies for use in the EU. See EMA guidance on XALKORI®.
  • If you would like to see the Patient Information Leaflet (PIL) or Summary of Product Characteristics (SPC) for XALKORI® these can be found at the electronic Medicines Compendium (eMC).

 

References

  1. XALKORI® Summary of Product Characteristics. June 2018
  2. European Medicines Agency. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002489/human_med_001592.jsp&mid=WC0b01ac058001d124. Last accessed: June 2018.

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professionals for specific, health-related advice and support.

PP-XLK-GBR-0766 / June 2018